Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
about
Structural mechanism of serum amyloid A-mediated inflammatory amyloidosisInvariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid AMonitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinicDifferential denaturation of serum proteome reveals a significant amount of hidden information in complex mixtures of proteinsSerum amyloid A is elevated in the serum of lung cancer patients with poor prognosisAssociation of serum amyloid A protein and peptide fragments with prognosis in renal cancer.Immunologic functions as prognostic indicators in melanomaProtein signatures for survival and recurrence in metastatic melanoma.An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoringExpression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinomaProteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutationProtein signatures correspond to survival outcomes of AJCC stage III melanoma patients.Proteomics in melanoma biomarker discovery: great potential, many obstacles.C-reactive protein as a marker of melanoma progression.New Perspectives of "omics" Applications in Melanoma Research.Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasThe prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer.MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive ProteinVitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma.Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.Cutaneous melanoma: a model to study cancer metastasis.Prognostic tissue markers in melanoma.Protein and non-protein biomarkers in melanoma: a critical update.Pretreatment Serum Amyloid A and C - Reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study.Identification of tetranectin as a potential biomarker for metastatic oral cancer.Plasma proteomics analysis of tamoxifen resistance in breast cancer.Serum amyloid A1 is upregulated in human glioblastoma.The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
P2860
Q27683023-E4DFD410-68A7-46A4-9DAC-7483A2BB2F8FQ28294740-38185096-886F-4466-8CDB-9A0680FFFB33Q28483618-6D901071-895F-4C9B-84B9-9117DA5447E2Q28488743-BC9B9BB5-D631-463D-9F87-F2FBD1EBF547Q33587249-09A81AA3-83B0-470C-A531-0500A8422D91Q33597715-B471EF8E-350B-4A32-A4D5-CC93C5A5FCE6Q33835011-D227FA14-2D59-416C-920F-DC74F3528796Q33891766-71DC30E2-D385-48F9-80B0-C06637AA43FFQ33990542-568A0C89-A73E-423E-AFF6-B1BF02A749DCQ34216967-51B023B6-54C8-4E46-957C-469323BF46EBQ34392042-627E8F4A-0251-4AA2-9AC5-D5E943BD5438Q34599527-D5E643D4-4D30-47AA-BE53-0D1BA16D8C0EQ34842139-3C6897A7-0415-4EE3-992B-139D053B6D3EQ35374035-CD193DD7-B905-47EB-88D1-7BB49049861CQ35419890-5B35AE85-438B-4211-91D9-1483371F6B3DQ35670683-5244DF97-8225-4F70-8B3A-C7152CB3EDF0Q35845352-7CEF4832-8F17-438F-A8BD-11BFEC51F478Q36121363-C8CAD2AA-DCB4-4ACE-84BD-3773F78727A0Q36147848-A2E53B04-6C39-4C95-B588-48E23C85A4EBQ37137938-392E93B0-9480-47B8-B639-653CBAAE8BA2Q37384738-C760EEA4-110D-4343-9258-1027412F217AQ37598057-C739F76D-F2A7-4A67-91FC-D41A2347DD66Q37605787-3CE24EFC-9A39-4349-9510-1DBA0831B305Q37863622-75973678-386F-4D15-B0F7-3FE7406D1718Q37924320-689464CB-2636-4D5F-B879-E8A74A37FE6DQ38050990-9B475E79-BC40-4486-B91E-0077A6BFF537Q40123094-8BE2FB46-E415-428B-AB45-84E05CCBE630Q42409163-23B2B352-8BA3-4A9D-9D5E-64EEF6967379Q44493749-28F63093-D0BA-4803-BC85-A242EBBC7628Q48137968-20891BF7-F079-4DAF-80E8-398BCEB29CDFQ52646495-06B6BBD0-3C04-435A-912A-E13065861C71
P2860
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
@ast
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
@en
type
label
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
@ast
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
@en
prefLabel
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
@ast
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
@en
P2093
P50
P356
P1476
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
@en
P2093
Heike Matzk
Michael Neumaier
Peter Findeisen
Teresa Peccerella
P304
P356
10.1200/JCO.2008.18.0554
P407
P577
2009-03-23T00:00:00Z